MedPharm moves into $4M expansion of its North Carolina facility

5 Dec 2019

Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.

MedPharm, experts in topical and transdermal drug delivery, has moved into its newly expanded facility in Durham, North Carolina.

MedPharm moves into $4M expansion of its North Carolina facility

The $4-million expansion has tripled the facility’s footprint to approximately 25,000 sq. ft significantly expanding capacity and supporting MedPharm’s continued commitment to the topical and transdermal market.

Investment into the site was made following increased demand for MedPharm’s topical and transdermal services. The expansion covers pre-formulation and formulation development, in vitro release, in vitro penetration/permeation, tissue culture, analytical/bioanalysis, custom device development and tissue engineering. In addition, the new space will include dedicated innovation, microbiology and histology laboratories.

“We are excited to be able to offer an expanded and unmatched level of services from our facility in the North Carolina Research Triangle Park area”, commented Eugene Ciolfi MedPharm’s President and CEO. “The expanded space has a streamlined workflow that segregates phases of work and makes transition through each project more efficient with complimentary equipment positioned where it’s most needed.”

The new laboratory expands capacity for MedPharm’s proprietary models which de-risk its customers’ development programs as it accommodates automated and high throughput analytical instrumentation to improve turnaround times and elevate the consistent quality of data for clients.

The facility’s unique, dedicated innovation Lab will allow MedPharm to continue its pioneering approach to the development of custom performance testing models to meet unmet customer needs in the topical and transdermal markets. This investment also means that MedPharm can react quickly to solving project-specific problems for its customers and stay at the forefront of the latest scientific breakthroughs and technology.

The expansion will also create over 100 new highly skilled scientific and strategic positions in Research Triangle Park in North Carolina.

Read More

Related news

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

15 Jan 2020

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

Read more 
Catalent launches direct-to-patient clinical supply services

Catalent launches direct-to-patient clinical supply services

14 Jan 2020

Multiple options provide increased flexibility for sponsors.

Read more 
Biogen to acquire novel clinical-stage asset from Pfizer

Biogen to acquire novel clinical-stage asset from Pfizer

14 Jan 2020

PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.

Read more 
French regulator agrees to partial resumption of Tellomak trial patient recruitment

French regulator agrees to partial resumption of Tellomak trial patient recruitment

14 Jan 2020

The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...

Read more 
Lupin could face FDA regulatory action over Tarapur API facility

Lupin could face FDA regulatory action over Tarapur API facility

13 Jan 2020

India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.

Read more 
Partnership formed to develop and commercialise ready-to-use medicine

Partnership formed to develop and commercialise ready-to-use medicine

13 Jan 2020

The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.

Read more 
ReadCoor to commercially launch spatial sequencing platform

ReadCoor to commercially launch spatial sequencing platform

10 Jan 2020

Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.

Read more 
CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more